Solidifying Perrigo’s leadership position in topical foam-based generic prescription pharmaceuticals, the company announced it has signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals.
Perrigo announced that it has initiated market launch and made its first shipments of minoxidil 5% foam, which is a generic version of Rogaine 5% foam hair regrowth treatment, to its retail and wholesale customers. Minoxidil 5% foam is marketed under store- or own-label brands.
Perrigo last week announced that it has received final Food and Drug Administration approval for its generic prescription allergy remedy desloratadine 5 mg, the generic equivalent to Schering-Plough's Clarinex.
Perrigo this summer developed a healthcare professional outreach strategy, educating pediatricians, for example, around the company’s new infants’ and children’s acetaminophen dosing and packaging changes.